Adam Rosenberg has been named the CEO of Cambridge, MA-based Rodin Therapeutics, a startup seeded by Atlas Venture in 2013 and run, up until now, by Atlas partner Bruce Booth. Rosenberg was previously the CEO of Medford, MA-based Telos Therapeutics, a startup developing small molecule drugs for neurological disorders. He’ll remain in charge of Teleos until the company hires a successor. Rodin, meanwhile, is developing an epigenetic drug—an inhibitor of histone deacetylase 2 (HDAC2)—as a potential cognitive booster for neurodegenerative diseases like Alzheimer’s, Parkinson’s and post traumatic stress disorder.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler